Eduardo Martins MD, DPhil

Dr Eduardo Bruno Martins joined Sagimet in February 2021, bringing more than 20 years of experience as a leader in the US and global biopharmaceutical industry. Dr Martins has worked in various therapeutic areas, including hepatology, vaccines, allergy and immunology, orphan diseases, and oncology, from translational research to Phase 4 clinical studies. His previous experience includes leadership of large-scale multinational clinical trials as well as building and leading multifunctional global teams in large pharmaceutical and small biotechnology companies. Most recently at AbbVie, Dr Martins was vice president of clinical development and led the clinical development of cenicriviroc for nonalcoholic steatohepatitis (NASH) and a collaboration with Verily (an Alphabet company) on artificial intelligence and virtual staining applied to liver biopsy.

Before joining AbbVie, Dr Martins served as vice president of clinical development at Allergan. Previously, he was a member of the executive leadership team as senior vice president of liver and infectious disease drug development at Eiger Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of chronic hepatitis D and orphan diseases. Before that, he held leadership positions at Gilead Sciences, Genentech, Dynavax Technologies, Intermune, SciClone Pharmaceuticals, University Hospital, Federal University of Rio de Janeiro, Brazil, and the Organisation Mondiale d’Endoscopie Digestive. He holds a doctorate (DPhil) degree from the University of Oxford (UK) and an MD from Federal University of Rio de Janeiro (Brazil).